Section Arrow
Quote
CNTB.NASDAQ
- Connect Biopharma Holdings Limited
Quotes are at least 15-min delayed:2026/04/15 09:41 EDT
Regular Hours
Last
 3.07
+0.02 (+0.66%)
Day High 
3.08 
Prev. Close
3.05 
1-M High
3.82 
Volume 
5.50K 
Bid
3.03
Ask
3.07
Day Low
3.03 
Open
3.08 
1-M Low
2.55 
Market Cap 
172.39M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 2.81 
20-SMA 2.93 
50-SMA 2.74 
52-W High 3.82 
52-W Low 0.65 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.00/-0.92
Enterprise Value
172.76M
Balance Sheet
Book Value Per Share
0.74
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
64.00K
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
IMMPImmutep Limited0.8799+0.5651+179.51%-- 
LIMNLiminatus Pharma Inc0.196+0.0162+9.01%-- 
ALLOAllogene Therapeutics1.885-0.395-17.32%-- 
LNAILunai Bioworks Inc.0.2984-0.0404-11.92%-- 
RVMDRevolution Medicines149.035+2.025+1.38%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.